×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SUPN – supernus pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SUPN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/10
07:18 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
12/9
07:00 am
supn
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
Medium
Report
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
12/3
06:31 pm
supn
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference [Yahoo! Finance]
12/3
04:05 pm
supn
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
Low
Report
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
11/26
02:19 pm
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
11/24
06:21 pm
supn
Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 [Yahoo! Finance]
Low
Report
Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 [Yahoo! Finance]
11/21
06:11 pm
supn
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/21
04:06 pm
supn
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
04:01 pm
supn
supernus pharmaceuticals, inc.
MISS
Report
-17.4%
supernus pharmaceuticals, inc.
8/5/2025
04:05 pm
supn
supernus pharmaceuticals, inc.
BEAT
Report
13.1%
supernus pharmaceuticals, inc.
5/6/2025
04:08 pm
supn
supernus pharmaceuticals, inc.
MISS
Report
-4.6%
supernus pharmaceuticals, inc.
2/25/2025
04:01 pm
supn
supernus pharmaceuticals, inc.
MISS
Report
-2.7%
supernus pharmaceuticals, inc.
Date
Time
Symbol
Headline
Impact
11/24
06:17 pm
supn
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 21 Filed by: NEWHALL CHARLES W III
Low
Report
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 21 Filed by: NEWHALL CHARLES W III
11/17
08:55 am
supn
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 13 Filed by: Bhatt Padmanabh P.
Low
Report
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 13 Filed by: Bhatt Padmanabh P.
11/14
06:27 pm
supn
Form SCHEDULE 13G/A SUPERNUS PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SCHEDULE 13G/A SUPERNUS PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC
11/6
05:02 pm
supn
Form 10-Q SUPERNUS PHARMACEUTICALS For: Sep 30
Low
Report
Form 10-Q SUPERNUS PHARMACEUTICALS For: Sep 30
11/4
04:18 pm
supn
Form 8-K SUPERNUS PHARMACEUTICALS For: Nov 04
High
Report
Form 8-K SUPERNUS PHARMACEUTICALS For: Nov 04
10/21
05:05 pm
supn
Form 8-K SUPERNUS PHARMACEUTICALS For: Oct 21
Neutral
Report
Form 8-K SUPERNUS PHARMACEUTICALS For: Oct 21
10/16
04:11 pm
supn
Form 8-K/A SUPERNUS PHARMACEUTICALS For: Jul 31
Low
Report
Form 8-K/A SUPERNUS PHARMACEUTICALS For: Jul 31
10/10
05:33 pm
supn
Form 4 SUPERNUS PHARMACEUTICALS For: Oct 09 Filed by: Khattar Jack A.
Low
Report
Form 4 SUPERNUS PHARMACEUTICALS For: Oct 09 Filed by: Khattar Jack A.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
Supernus to Acquire CNS Portfolio from US WorldMeds
19.0%
3/30 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 6.8%
11/7 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. 6.1%
4/3 Form 8-K SUPERNUS PHARMACEUTICALS For: Mar 30 5.7%
11/8 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at Berenberg Bank from a "buy" rating to a "hold" rating. 5.1%
8/27 Form 4 SUPERNUS PHARMACEUTICALS For: Aug 23 Filed by: Khattar Jack A. 5.1%
3/30 Supernus Provides Business Update 4.8%
3/4 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.4%
6/25 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.0%
4/24 Supernus to Host First Quarter Results Earnings Conference Call 3.3%
3/30 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 6.8%
11/7 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. 6.1%
4/3 Form 8-K SUPERNUS PHARMACEUTICALS For: Mar 30 5.7%
11/8 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at Berenberg Bank from a "buy" rating to a "hold" rating. 5.1%
8/27 Form 4 SUPERNUS PHARMACEUTICALS For: Aug 23 Filed by: Khattar Jack A. 5.1%
3/30 Supernus Provides Business Update 4.8%
3/4 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.4%
6/25 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.0%
4/24 Supernus to Host First Quarter Results Earnings Conference Call 3.3%
TOP News Decliners
11/5
Q3/2019 9/30/2019 EPS 0.540 ZacksConsensus 0.590 ActVsEst (0.050) - Miss
-31.6%
8/6 Q2/2019 6/30/2019 EPS 0.610 ZacksConsensus 0.560 ActVsEst 0.050 - Beat -15.0%
2/25 Supernus Announces Fourth Quarter and Full Year 2019 Financial Results -14.9%
2/26 Why Supernus Pharmaceuticals Plunged 15% Today [The Motley Fool] -7.8%
8/27 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.0%
5/7 Form 8-K SUPERNUS PHARMACEUTICALS For: May 07 -3.5%
5/29 Supernus to Present at the Jefferies 2019 Global Healthcare Conference -3.5%
9/25 Form 8-K SUPERNUS PHARMACEUTICALS For: Sep 25 -3.4%
1/23 Form 8-K SUPERNUS PHARMACEUTICALS For: Jan 21 -2.6%
4/30 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) had its price target raised by analysts at Piper Sandler from $17.00 to $25.00. They now have a "neutral" rating on the stock. -2.5%
8/6 Q2/2019 6/30/2019 EPS 0.610 ZacksConsensus 0.560 ActVsEst 0.050 - Beat -15.0%
2/25 Supernus Announces Fourth Quarter and Full Year 2019 Financial Results -14.9%
2/26 Why Supernus Pharmaceuticals Plunged 15% Today [The Motley Fool] -7.8%
8/27 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.0%
5/7 Form 8-K SUPERNUS PHARMACEUTICALS For: May 07 -3.5%
5/29 Supernus to Present at the Jefferies 2019 Global Healthcare Conference -3.5%
9/25 Form 8-K SUPERNUS PHARMACEUTICALS For: Sep 25 -3.4%
1/23 Form 8-K SUPERNUS PHARMACEUTICALS For: Jan 21 -2.6%
4/30 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) had its price target raised by analysts at Piper Sandler from $17.00 to $25.00. They now have a "neutral" rating on the stock. -2.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: